Nordic Nanovector Presents Preclinical Data at AACR 2018
Oslo, Norway, 16 April 2018 Nordic Nanovector ASA (OSE: NANO) announces that a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin’s lymphoma (NHL) was presented yesterday at the American Association of Cancer Research (AACR) Annual Meeting 2018 in Chicago, USA. The company previously announced the publication of the poster abstract (abstract 848) on 15 March 2018. The poster was entitled “In vitro and in vivo evaluation of the beta-emitting lutetium-177 labeled anti-CD37 antibody